Towa
Pharmaceutical
Towa Presence in Japan
Major Group
Companies
Greencaps Pharmaceutical.Co., Ltd.
Producing soft capsules for pharmaceutical products. Headquarters: Fujinomiya, Shizuoka, Japan.
Sunsho Pharmaceutical Co., Ltd.
Manufacturing and selling of ethical and OTC drugs. Capsules technology. Headquarters: Fuji, Shizuoka, Japan
J-DOLPH Pharmaceutical Co., Ltd.
Manufacturing and selling of ethical drugs. Headquarters: Koka, Shiga, Japan.
Daichi kasei, Co., Ltd.
R&D and manufacturing of APIs and intermediates. Headquarters: Fukusaki, Kanzaki, Hyogo, Japan.
Other health
services companies
T Square Solutions Co., Ltd.
Providing healthcare-related IT services. Headquarters: Settu, Osaka, Japan
Protosera Inc.
Disease risk testing service business and research and development of diagnostic drugs. Headquarters: Osaka, Osaka
We ensure to cover all the phases
of our value chain in our products
Active Pharmaceutical Ingredients (APIs)
Research and Development of Finished Dosage Forms (FDFs)
Regulatory Affairs and Quality Control
Manufacturing and Stable product supply
Marketing and distribution
Towa Pharmaceutical
In numbers
0st
generic medicines company ranking in Japan
+0B€
in sales
+0M€
R&D investment
+0
medicinal effect and mechanism
+0
employees
+0
products
+0B
tablets per year
0
Research centers
0
Manufacturing plant
Entering new
health-related business
As one of our challenges, we aim for creating a future that provides full coverage of medical expenses to care for pre-symptomatic disease and prevention for society with a long and healthy life expectancy.
In line with our vision of contributing to people’s health, we will work to create new health-related businesses that are suited to the new medical system, while acquiring new techniques and integrating them with completely new knowledge and technologies.
Specifically, we will help build an infrastructure to create ideal local communities, and contribute to extending healthy life expectancy by providing necessary health promotion services to people in need of them.
Among our key measures, we will be launching testing services for determining disease risks, expanding the KENTO Healthcare Science Center, which opened in 2019 to conduct joint research with the National Cerebral and Cardiovascular Center to extend healthy life expectancy, and collecting/ utilizing information obtained from testing to provide appropriate health-related services.
Key measures
-
Building a foundation for extending healthy life expectancy by utilizing key data
-
Contributing to the Comprehensive Community Care System
-
Further enhancing the lineup of products and services to maintain and improve health
-
Entering disease risk testing service business
-
Creating synergies with existing businesses
